A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UCanADA
- Sponsors AbbVie
- 26 Mar 2018 Planned number of patients changed from 200 to 100.
- 10 Jun 2017 Biomarkers information updated
- 05 Apr 2017 Planned End Date changed from 1 Sep 2019 to 1 Feb 2022.